The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma

被引:38
作者
Hoskin, PJ
Sibtain, A
Daley, FM
Saunders, MI
Wilson, GD
机构
[1] Mt Vernon Canc Ctr, CR UK Tumour Biol & Radiat Therapy Grp, Northwood HA6 2RN, Middx, England
[2] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England
关键词
bladder cancer; hypoxia; pimonidazole; proliferation; vascularity;
D O I
10.1016/j.radonc.2004.03.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Hypoxia and proliferation are important determinants of radiation responsiveness; prospective measures of these before radiotherapy may enable individualisation of treatment schedules. Immunohistochemical techniques offer a potential means of achieving this in routine biopsy material. Material and methods: Cellular hypoxia as measured by pimonidazole fixation and immunohistochemistry has been evaluated in a series of human bladder cancers with dual staining of sections for pimonidazole and either the vascular markers, CD31/34, or proliferation markers, Ki-67 or cyclin A. Twenty one tumour specimens were examined suitable for the double staining technique. Results: The median hypoxic fraction was 9% (range 0-38). Seven tumours did not stain for pimonidazole and 11 exhibited necrosis. The mean vascular density ranged from 16.7 to 160.6 vessels per mm(2). The median hot spot count was 30 (range 16-43). There was a statistically significant increase in vessel density in hypoxic compared to oxic regions measured by both vessel density (P = 0.02) and hot spot count (P = 0.004). Proliferation indices decreased from oxic to hypoxic areas close to blood vessels. Conclusions: We have demonstrated that bladder cancer exhibits a range of hypoxia, proliferation and vascular density which may be used to form the basis for patient selection for hypoxia modification, accelerated radiotherapy and vascular targeting agents. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:159 / 168
页数:10
相关论文
共 42 条
[1]   GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding [J].
Airley, RE ;
Loncaster, J ;
Raleigh, JA ;
Harris, AL ;
Davidson, SE ;
Hunter, RD ;
West, CML ;
Stratford, IJ .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (01) :85-91
[2]   CELL INACTIVATION AND CELL-CYCLE INHIBITION AS INDUCED BY EXTREME HYPOXIA - THE POSSIBLE ROLE OF CELL-CYCLE ARREST AS A PROTECTION AGAINST HYPOXIA-INDUCED LETHAL DAMAGE [J].
AMELLEM, O ;
PETTERSEN, EO .
CELL PROLIFERATION, 1991, 24 (02) :127-141
[3]   Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state [J].
Arteel, GE ;
Thurman, RG ;
Raleigh, JA .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 253 (03) :743-750
[4]  
Beasley NJP, 2001, CANCER RES, V61, P5262
[5]   EFFECT OF HYPOXIA ON GROWTH AND RADIATION RESPONSE OF MAMMALIAN-CELLS IN CULTURE [J].
BEDFORD, JS ;
MITCHELL, JB .
BRITISH JOURNAL OF RADIOLOGY, 1974, 47 (562) :687-696
[6]  
Begg AC, 2001, ACTA ONCOL, V40, P924
[7]   Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts [J].
Bussink, J ;
Kaanders, JHAM ;
Rijken, PFJW ;
Martindale, CA ;
van der Kogel, AJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (01) :57-64
[8]  
Chaudhary R, 1999, ANTICANCER RES, V19, P3479
[9]   Hypoxic heterogeneity in human tumors - EF5 binding, vasculature, necrosis, and proliferation [J].
Evans, SM ;
Hahn, SM ;
Magarelli, DP ;
Koch, CJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (05) :467-472
[10]  
Giatromanolaki A, 2001, CANCER RES, V61, P7992